Bajaj Healthcare launches antiviral drug ‘Favijaj’

04 May 2021

Bajaj Healthcare has launched ‘Favijaj’ (Favipiravir) an antiviral drug used for treating patients suffering from influenza virus and has proved to be effective over COVID patients. The company has received approval from India's drug regulator, to manufacture and market ‘Favijaj’ the oral Favipiravir approved medication in India for the treatment of COVID-19 from May 04, 2021.

‘Favijaj’tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate Covid-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Related Bajaj Healthcare Ltd. Links:

Bajaj Healthcare Share Price

627.70 0.15 (0.02%) May 07, 18:03
1 Year Price Chart
Company Name CMP
Sun Pharma Inds. 679.50
Dr. Reddys Lab 5173.55
Lupin 1195.60
Piramal Enterprises 1670.45
Cadila Healthcare 603.10
View more..
Sensex vs Bajaj Healthcare
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323